Patients were given the choice of either treatment.
There were no significant effects of either treatment on any other variable of anxiety or cardiovascular indices.
A combination of tDCS with the antidepressant drug setraline (generic Zoloft) had twice the effect of either treatment alone.
We took three sub-samples (5×5 cm and 6 cm depth) from cells with an organic horizon thickness of 7.5 cm in all replicates of either treatment.
As shown in Fig. S3E, no significant effects of either treatment were found on peak firing rates, spontaneous firing rates, orientation selectivity, or visual responsiveness for this set of neurons.
Furthermore, combined treatment with 10 MPa static HP and TGF-β1 led to a synergistic increase in collagen/WW to 15.3±2.9%; the increase in collagen/WW was statistically greater than the sum of either treatment alone.
This increase indicated an additive effect between 10 MPa static HP and TGF-β1, as the effect of their combined use on HA was equal to the sum of the effects of either treatment alone.
Because this error did not compromise blinding of either treatment allocation by investigators in the field, or the assessors assigned to perform the checkups, the viability of the study was not considered to have been impaired, particularly as such a distribution could have occurred naturally as a result of some investigators using only part of their allocation of numbered envelopes.
There was a significant effect of breed on albumen corticosterone levels (mean±SEM; RJF: 1.38±0.12 ng/ml, WL: 0.88±0.1 ng/ml; ANOVA, F1,21 = 38.7, p<0.001), but no effect of treatment, and no effects were observed of either treatment or breed on yolk levels.
Older age was significantly associated with lower probability of use of either treatment.
The adverse events that led to discontinuation occurred in <2% of either treatment group.
